BLA 761152 · Omeros Corp
Yartemlea
Narsoplimab-Wuug
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Dec 23, 2025: To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 23, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 1 recruiting
FAERS reports
21
21 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 20, 2026.
YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )
Mechanism: Narsoplimab-wuug inhibits MASP-2, the effector enzyme of the lectin pathway of the complement system, blocking lectin-dependent activation of complement component 3 (C3) and C4 without affecting the classical and alternative pathways of complement. In hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), MASP-2 inhibition is thought to prevent lectin pathway-mediated cellular injury, including endothelial cell injury in small blood vessels.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- YARTEMLEA · NARSOPLIMAB-WUUG · INJECTION, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Narsoplimab" as an intervention, any sponsor and status, largest first.
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyPivotal-lookingTerminated
Omeros CorporationIndustry
NCT03608033 · 360 participants · Start Apr 5, 2018 · Primary completion Jan 12, 2024
Drug: OMS721 · For: IgA Nephropathy
Sites: Florence, Alabama; Mesa, Arizona; Phoenix, Arizona · 139 sites in all
Omeros CorporationIndustry
NCT02222545 · 58 participants · Start Nov 2, 2014 · Primary completion Jan 30, 2020
Drug: OMS721 · For: Thrombotic Microangiopathies
Sites: Duarte, California; Rochester, Minnesota; New York, New York · 24 sites in all
Omeros CorporationIndustry
NCT02682407 · 31 participants · Start Mar 10, 2016 · Primary completion Aug 25, 2020
Drug: OMS721 (narsoplimab) · For: IgAN; LN; MN and 1 more
Sites: Denver, Colorado; Augusta, Georgia; Lawrenceville, Georgia · 12 sites in all
Omeros CorporationIndustry
NCT05855083 · 18 participants (planned) · Start May 1, 2023 · Primary completion Dec 2025
Drug: Biological: narsoplimab · For: Thrombotic Microangiopathies; Hematopoietic Stem Cell Transplantation
Sites: San Diego, California; Gainesville, Florida; Boston, Massachusetts · 16 sites in all
- Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromePivotal-lookingTerminated
Omeros CorporationIndustry
NCT03205995 · 6 participants · Start May 2, 2018 · Primary completion Feb 2, 2021
Drug: OMS721 (narsoplimab) · For: Thrombotic Microangiopathies; Atypical Hemolytic Uremic Syndrome
Sites: Chicago, Illinois; Vilnius, Lithuania; Lodz, Poland · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- thrombotic microangiopathy5
- drug ineffective4
- thrombocytopenia3
- acute graft versus host disease in skin2
- acute kidney injury2
- cytopenia2
- disease recurrence2
- gastrointestinal haemorrhage2
- hypertension2
- hypervolaemia2
- respiratory failure2
- acute respiratory distress syndrome1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 4 |
| 2025 | 2 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled SK, Claes K, Goh YT, et al. · J Clin Oncol 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
- MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
Elhadad S, Chapin J, Copertino D, et al. · Clin Exp Immunol 2021 · Clinical Trial, Research Support, N.I.H., Extramural
- Targeting the Roots of Kidney Disease: Systematic Review of the Therapies Targeting the Complement System.
Roman M, Nowicki M · Medicina (Kaunas) 2025 · Systematic Review
Sponsor: Omeros Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.